Pfizer (NYSE:PFE) Given New $33.00 Price Target at Guggenheim

Pfizer (NYSE:PFE) had its price objective boosted by Guggenheim from $31.00 to $33.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Guggenheim‘s price target points to a potential upside of 6.15% from the company’s current price.

A number of other equities research analysts have also recently weighed in on the stock. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday, October 10th. Bank of America decreased their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. HSBC upped their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock a “hold” rating in a research note on Thursday, September 10th. BMO Capital Markets decreased their price objective on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a report on Monday, July 13th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 9th. Five research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $29.94.

Pfizer Stock Performance

Shares of PFE stock traded up $0.30 during trading hours on Thursday, reaching $31.09. The stock had a trading volume of 11,381,664 shares, compared to its average volume of 39,689,750. The firm has a market capitalization of $177.20 billion, a PE ratio of 44.37, a price-to-earnings-growth ratio of 2.04 and a beta of 0.31. The firm has a 50-day simple moving average of $28.69 and a 200-day simple moving average of $26.86. Pfizer has a twelve month low of $23.62 and a twelve month high of $31.44. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.74 by $0.13. Pfizer had a net margin of 6.34% and a return on equity of 19.98%. The firm had revenue of $16.58 billion during the quarter, compared to analysts’ expectations of $15.85 billion. During the same quarter in the prior year, the firm earned $0.87 EPS. Pfizer’s quarterly revenue was down .4% on a year-over-year basis. As a group, equities analysts forecast that Pfizer will post 2.94 earnings per share for the current year.

Institutional Trading of Pfizer

A number of hedge funds and other institutional investors have recently made changes to their positions in PFE. BlackRock Inc. raised its holdings in Pfizer by 6.3% during the 2nd quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock worth $12,754,464,000 after buying an additional 31,412,883 shares during the period. State Street Corp increased its position in shares of Pfizer by 1.8% in the second quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company’s stock worth $7,394,749,000 after acquiring an additional 5,501,032 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Pfizer by 11.1% in the first quarter. Bank of New York Mellon Corp now owns 53,879,900 shares of the biopharmaceutical company’s stock worth $1,512,948,000 after acquiring an additional 5,364,929 shares in the last quarter. Bank of America Corp DE acquired a new stake in shares of Pfizer during the second quarter valued at approximately $1,049,602,000. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Pfizer by 0.8% during the first quarter. Dimensional Fund Advisors LP now owns 36,422,799 shares of the biopharmaceutical company’s stock valued at $1,022,606,000 after acquiring an additional 293,029 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer beat Q3 earnings and revenue expectations and raised its 2026 forecast to $62–$64 billion in revenue and adjusted EPS of $2.95–$3.05. Launched and acquired products grew 32% operationally, while non-COVID products rose 7%. Article: Pfizer: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Scotiabank raised its price target to $35 and reiterated “sector outperform,” adding to the positive outlook surrounding the results. Scotiabank analyst recommendations
• Positive Sentiment: A recent TipRanks article described Pfizer’s dividend as well-covered and the stock’s valuation as modest, potentially appealing to income-focused investors. Article: Pfizer Stock Looks Attractive for Income Investors
• Neutral Sentiment: Analyst views remain mixed: RBC raised its target to $28 and UBS and Citi to $30, but all maintained neutral or sector-perform ratings—targets below the price cited in the reports. RBC analyst recommendations
• Negative Sentiment: Revenue was roughly flat as COVID product sales continued to decline, and margin pressure remains a concern. Pfizer must sustain growth in newer products and deliver on cost savings and pipeline milestones to make the raised outlook durable. Article: Pfizer Just Raised Guidance. The Bigger Test Comes Next

About Pfizer

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.